Bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol
Autor: | Nazer Hasan, Shalini Chawla, Bhupinder Singh Kalra, Kirti Nirmal, Rohit Chawla, Shubha Singhal, Anil Dhal |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male musculoskeletal diseases medicine.medical_specialty WOMAC Turmeric extract India Pain Medicine (miscellaneous) Osteoarthritis Physical function 03 medical and health sciences Curcuma 0302 clinical medicine Double-Blind Method Internal medicine medicine Humans Knee Pharmacology (medical) Prospective Studies Adverse effect Acetaminophen Pain Measurement 030203 arthritis & rheumatology lcsh:R5-920 Plant Extracts business.industry Research Turmeric Middle Aged Osteoarthritis Knee Bioavailable medicine.disease Bioavailability Clinical trial Treatment Outcome Paracetamol 030220 oncology & carcinogenesis Non inferiority trial Female lcsh:Medicine (General) business |
Zdroj: | Trials, Vol 22, Iss 1, Pp 1-11 (2021) Trials |
ISSN: | 1745-6215 |
DOI: | 10.1186/s13063-021-05053-7 |
Popis: | Background To compare the efficacy and safety of bioavailable turmeric extract versus paracetamol in patients with knee osteoarthritis (OA). Methods In this randomized, non-inferiority, controlled clinical study, patients of knee OA were randomized to receive bioavailable turmeric extract (BCM-95®) 500 mg capsule two times daily or paracetamol 650 mg tablet three times daily for 6 weeks. The primary outcome measure was Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale. The secondary outcome measures were WOMAC total, WOMAC stiffness, and WOMAC physical function scores. Responder analysis of individual patients at different levels (≥ 20%, ≥ 50%, and ≥ 70%) for WOMAC score was calculated. TNF alpha and CRP levels were evaluated and adverse events (AE) were also recorded. Results Seventy-one and seventy-three knee OA patients, respectively in bioavailable turmeric extract and paracetamol groups, completed the study. Non-inferiority (equivalence) test showed that WOMAC scores were equivalent in both the groups (p value d) of 0.5 whereas CRP and TNF-α were better reduced with turmeric extract than paracetamol. After 6 weeks of treatment, WOMAC total score, pain, stiffness, and function scores got a significant improvement of 23.59, 32.09, 28.5, and 20.25% respectively with turmeric extract. In the turmeric extract group, 18% of patients got more than 50% improvement and 3% of patients got more than 70% improvement in WOMAC pain and function/stiffness score and none of the patients in the paracetamol group met the criteria. CRP and TNF-α got significantly reduced (37.21 and 74.81% respectively) in the turmeric extract group. Adverse events reported were mild and comparatively less in the turmeric extract group (5.48%) than in the paracetamol group (12.68%). Conclusion The results of the study suggest that bioavailable turmeric extract is as effective as paracetamol in reducing pain and other symptoms of knee osteoarthritis and found to be safe and more effective in reducing CRP and TNF-α. Trial registration Clinical Trials Registry – India CTRI/2017/02/007962. Registered on 27 February 2017 |
Databáze: | OpenAIRE |
Externí odkaz: |